The therapeutic efficacy of propranolol in children with recurrent primary epistaxis

被引：5

作者：

Bjelakovic, Bojko ^{[1
,2
]}

Bojanovic, Mila ^{[2
,3
]}

Lukic, Stevo ^{[2
,4
]}

Saranac, Ljiljana ^{[1
,2
]}

Vukomanovic, Vladislav ^{[5
,6
]}

Prijic, Sergej ^{[5
]}

Zivkovic, Nikola ^{[7
]}

Randjelovic, Dusica ^{[1
]}

机构：

[1] Ctr Clin, Pediat Clin, Nish, Serbia

[2] Univ Nis, Fac Med, Nish, Serbia

[3] Ctr Clin, Otorhinolaryngol Clin, Nish, Serbia

[4] Ctr Clin, Neurol Clin, Nish, Serbia

[5] Dr Vukan Cupic, Mother & Child Hlth Inst, Belgrade, Serbia

[6] Univ Belgrade, Fac Med, Belgrade 11001, Serbia

[7] Univ Nis, Inst Pathol, Fac Med, Nish, Serbia

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2013年 / 7卷

关键词：

beta-blocker; epistaxis; children; HEREDITARY HEMORRHAGIC TELANGIECTASIA; ENDOTHELIAL-CELLS;

D O I：

10.2147/DDDT.S41756

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

We hypothesized that some characteristics of beta-blockers, including negative inotropic, peripheral vasoconstrictor, and antiangiogenic effects, might be potentially useful in treating children with epistaxis. From June 2010 to March 2012, a total of seven children with recurrent primary epistaxis resistant to conventional management were observed at our institution. An overall effectiveness of propranolol was noted in all seven children when given a dose of 1.5-2 mg/kg/day (divided into three doses) as a second line therapy for terminating epistaxis. Based on our first experience, we believe that propranolol could be a favorable treatment option for patients with primary epistaxis.

引用

页码：127 / 129

页数：3

共 15 条

[1] Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia [J].

Albinana, Virginia ;

Recio-Poveda, Lucia ;

Zarrabeitia, Roberto ;

Bernabeu, Carmelo ;

Maria Botella, Luisa .

THROMBOSIS AND HAEMOSTASIS, 2012, 108 (01) :41-53

[2] Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion [J].

Annabi, Borhane ;

Lachambre, Marie-Paule ;

Plouffe, Karine ;

Moumdjian, Robert ;

Beliveau, Richard .

PHARMACOLOGICAL RESEARCH, 2009, 60 (05) :438-445

[3] Epistaxis in healthy children requiring hospital admission [J].

Brown, NJ ;

Berkowitz, RG .

INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2004, 68 (09) :1181-1184

[4] Variceal bleeding and portal hypertensive gastropathy [J].

Dagher, L ;

Burroughs, A .

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2001, 13 (01) :81-88

[5] Propranolol Safety Profile in Children [J].

El-Shabrawi, Mortada ;

Hassanin, Fetouh .

CURRENT DRUG SAFETY, 2011, 6 (04) :259-266

[6] CHOOSING THE RIGHT BETA-BLOCKER - A GUIDE TO SELECTION [J].

HAMPTON, JR .

DRUGS, 1994, 48 (04) :549-568

[7] Propranolol suppresses angiogenesis in vitro: Inhibition of proliferation, migration, and differentiation of endothelial cells [J].

Lamy, Sylvie ;

Lachambre, Marie-Paule ;

Lord-Dufour, Simon ;

Beliveau, Richard .

VASCULAR PHARMACOLOGY, 2010, 53 (5-6) :200-208

[8] Propranolol for severe hemangiomas of infancy [J].

Leaute-Labreze, Christine ;

de la Roque, Eric Dumas ;

Hubiche, Thomas ;

Boralevi, Franck ;

Thambo, Jean-Benoit ;

Taieb, Alain .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 358 (24) :2649-2651

[9] Epistaxis: update on management [J].

Melia, Louise ;

McGarry, Gerald W. .

CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2011, 19 (01) :30-35

[10] The pathology of visible blood vessels on the nasal septum in children with epistaxis [J].

Montague, Mary-Louise ;

Whymark, Andrew ;

Howatson, Allan ;

Kubba, Haytham .

INTERNATIONAL JOURNAL OF PEDIATRIC OTORHINOLARYNGOLOGY, 2011, 75 (08) :1032-1034

← 1 2 →